Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ548MR)

This product GTTS-WQ548MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ548MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12564MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ6600MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ7428MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ3251MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ7031MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ6753MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ10997MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ6978MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW